This trial is evaluating whether cTBS will improve 2 primary outcomes in patients with Consolidation. Measurement will happen over the course of Performance as measured at the end of learning (single day experiment).
This trial requires 120 total participants across 5 different treatment groups
This trial involves 5 different treatments. CTBS is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
To the best of this authors knowledge, CTPBs have not demonstrated an improved therapeutic effect as compared to a placebo; however, some studies are still undergoing peer-review.
Speech is the production of and understanding of sounds. The disorder includes impairment of verbal expression, oral reading, the ability to listen to speech and to understand speech. speech disorders may not necessarily be present.\n
Around 12 million Americans have difficulty in the expression of language a year. These difficulties can be due to a number of factors including age, brain diseases, and other disorders.
This article highlights the latest developments in clinical trials of ctbs for therapeutic use. The data also provides clinical evidence for the efficacy and tolerability of ctbs in treating patients with ctbs-related neurological conditions.
Although speech therapy is not usually a part of treatment, there is a growing trend toward specialized speech therapy. More research is needed into the extent of speech therapy's role in managing speech disorders in other populations with communication disorders.
Patients with laryngectomy suffer a significant drop in their quality of life, and their subjective satisfaction with therapy is often low. Speech therapy may have a limited role in facilitating improved self-esteem and quality of life in laryngectomized patients, but further research is needed.
Speech is an important part of a person's experience and is particularly important when they are a child. Many people, however, experience the stigma of having a speech disorder (SDD), such as an stutter, making them feel uneasy, anxious or intimidated. This research will help inform and support others whose children possess a speech disorder to feel as well as possible.
Because the vocal tract is so critical for the sound of the human voice, the study of congenital voice disorders is of great importance. The underlying cause of this dysfunction requires further exploration.
Older people with stuttering are more likely to be male and have higher education and higher-risk lifestyles in a population of people with stuttering. Speech professionals should be aware of their patients' demographics so they can support them in recovery and treatment at any age.
There is a primary cause of speech which is the [language of articulation] rather than [language of the language-using organism.] The [language-of-articulation] of speech is the result of [the interaction of factors that affect speech-like (sic) function in the mouth|-like function] rather than [the primary cause of language].
Our studies suggest a model in which CTB promotes ER stress, which in turn activates Bax and Bid in MCT cells through the PERK/eIF3 signaling pathway. These data are consistent with the model that CTB promotes apoptosis in neuronal cells through ER stress.
Common side effects of ctbs are headache, constipation, dizziness, and loss of hearing. Serious side effects were uncommon. Physicians should check side effects twice a day and call for further evaluation when the patient has persistent side effects or when there does not respond to ctbs. It seems the patient with ctbs also have poor quality of life.